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OBJECTIVES OF STUDY 
The objective of this study is to establish the glioma cell line from the clinical 
sample that obtained from HUSM Operation Theater. The establishment of glioma cell line 
can be confirmed by using immunocytochemistry technique as well as western blot method. 
In addition, this study are carried out in order to evaluate whether or not cells in a particular 
sample express antigen in question and also to determine which subcellular compartment 
are expressing the antigen. 
The establishments of glioma cell line were contributed for molecular and cellular 
study as well as to improve the treatment and therapy of glioma. 
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ABSTRACT 
A human malignant continuous cell line, named as GBM N was established from a patient 
diagnosed with recurrents glioblastoma multiforme which is grade IV glioma. This primary 
cell line has been serially subcultured until 6th passage in the standard culture media that 
presenting the existence of various marker. The aim of this study is to assess the 
morphology of cultured glioblastoma multiforme cells as well as to apply the confirmatory 
technique such as immunocytochemistry and western blotting method in order to confirm 
the biological and immunological characteristic of gliomas. Immunocytochemistry finding 
indicate this cell line retain the expression of Glial Fibrillary Acid Protein (GF AP) despite 
some previous study show no GF AP are exist in established glioma cell line. However, our 
study suggests, to prove the existence of GF AP in glioma cell line; we need to culture and 
subculture until 50th passage in where only the specific protein marker will be presented. 
Another technique used to confirm the establishment of glioma cell line is western blotting 
method which serves as total protein study in explaining the biology of tumor as well as to 
identify the protein that are very potential to cause human disease. 
We believe that the information regarding the establishment of GBM IV cell line will give 
benefits to all research community especially who have some interest to cellular and 
molecular study of cancer with the main purpose to improve glioma's treatment. 
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ABSTRAK 
Sel kultur selanjar bagi kanser manusia yang berbahaya dinamakan sebagai GBM IV telah 
ditubuhkan daripada pesakit yang didiagnosiskan sebagai glioblastoma multiforme 
berulangan, gred IV. Sel kultur primer ini telah dikultur dan disubkulturkan sehingga fasa 
yang ke-6 di dalam media kultur piawai di mana sel kultur primer ini mempersembahkan 
kehadiran pelbagai penanda protein. Tujuan penyelidikan ini dilakukan adalah untuk 
mengkaji morfologi sel glioblastoma multiforme yang telah dikulturkan dan juga untuk 
mengaplikasikan teknik-teknik pengesahan seperti immunositokimia dan "western blotting" 
dengan tujuan untuk mengesahkan ciri-ciri biologi dan immunologi bagi glioma. Penemuan 
immunositokimia menunjukkan bahawa sel kultur ini menahan ekspresi protein asid fibrial 
glial (GFAP) walaupun sesetengah penyelidikan sebelum ini menunjukkan tiada kewujudan 
GF AP dalam sel kultur glioma yang dibangunkan. Walaubagaimanapun, penyelidikan kami 
mencadangkan, untuk membuktikan kewujudan GF AP di dalam sel kultur glioma, kami 
perlu melakukan pengkulturan dan pengsubkulturan sehingga fasa yang ke-50 di mana 
hanya spesifik penanda protein akan hadir. Kaedah lain yang digunakan untuk 
mengesahkan penubuhan sel kultur glioma adalah teknik "western blotting" yang 
berperanan sebagai penyelidikan keseluruhan protein di dalam langkah menerangkan 
biologi tumor dan juga mengenalpasti protein yang sangat berpotensi untuk menyebabkan 
penyakit di kalangan manusia. 
Kami percaya bahawa maklumat berkenaan sel kultur primer ini akan memberi kebaikan 
kepada semua komuniti penyelidikan terutamanya kepada mereka yang berminat di dalam 
penyelidikan molekular dan selullar kanser dengan tujuan utama untuk meningkatkan 
rawatan bagi glioma. 
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1.0 INTRODUCTION AND LITERATURE REVIEW 
The pathogenesis of tumor growth and invasion depends both on host factors and on 
properties of the tumor cells. These entities are involved during tumor progression. 
However, it is difficult to know what contribution the tumor cells or the host tissue have in 
the invasive process (Bjerkvig eta/., 1989). To understand these phenomena further, there 
is a need of a fundamental research on how gene regulation can contribute to the 
development of tumorigenesis. Establishment of a pure primary cell lines is indeed an 
important factor to start the whole experiment rolling. 
1.1. Classification, grading and staging of Brain tumor 
Brain tumor encompasses neoplasms that originate in the brain itself (primary brain 
tumors) or involve the brain as a metastatic site (secondary brain tumors). The primary 
brain tumors include tumors of the brain parenchyma, meninges, cranial nerves and other 
intracranial structures (the pituitary and pineal glands). Secondary brain tumors, which 
originate elsewhere in the body and metastasize to the intracranial compartment, are the 
most common types of brain tumors (Schiff and Batchelor, 2006). 
Tumor classification is done by the pathologist microscopic examination. In 
concepts, brain tumor arises from different normal cells of the brain and spinal cord and the 
resulting neoplasms are designated accordingly (Burger and Cohen, 2004 ). Gliomas are 
primary Central Nervous System (CNS) tumors that are derived from glial cells, namely 
astrocytes, oligodendrocytes and ependymal cells (Moore and Psarros, 2005). Gliomas 
originate from glial cells, most often astrocytes. Sometimes the terms "astrocytoma" and 
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"glioma" are used interchangeably (St. Jude Children's Research Hospital, 2008). For glial 
tumors, tumor classification is achieved initially by assigning the lesion to one of these 
groups. The lesion is then placed among subsets of these groups. Thus, astrocytomas will 
be further subdivided since the term "astrocytoma" is non-specific as it includes different 
lesions of varying degrees of biological aggressiveness and potential cure. A common type 
of astrocytoma in children is "pilocytic astrocytoma," known for its slow rate of growth 
and, in many cases, surgical cure. Other forms of astrocytomas, e.g. the "fibrillary" types, 
infiltrate surrounding tissues and are more difficult to contain. A common additional class 
of brain tumors in children is the "embryonal" or "PNET" groups. The cerebellar 
medulloblastoma is the most common example (Burger and Cohen, 2004 ). 
Astrocytomas are tumors that arise from brain cells called astrocytes. Astrocytomas 
are of two main types- high grade and low grade. High-grade tumors grow rapidly and can 
easily spread through the brain. Low-grade astrocytomas are usually localized and grow 
slowly over a long period of time. High-grade tumors are much more aggressive and 
require very intensive therapy. The majority of astrocytic tumors in children are low-grade, 
whereas the majority in adults is high-grade. These tumors can occur anywhere in the brain 
and spinal cord (St. Jude Children's Research Hospital, 2008). 
According to the World Health Organization (WHO), astrocytomas can be graded 
depending on their cellular characteristics; for example, Grade I (usually juvenile pilocytic 
type), Grade II (diffuse fibrillary, gemistocytic types), Grade III (anaplastic type), or Grade 
IV (Glioblastoma Multifonne) (Brain Tumor Society, 2004). 
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This tumor also can be subclassified clinicopathologically into low grade 
(astrocytomas, grade I and II), intermediate grade (anaplastic astrocytomas, grade III) 
gliomas and the most malignant form (glioblastoma, grade IV) and tumor progression from 
lower to higher grades is not uncommon ( Onda et al., 1999). 
In general, astrocytomas are graded from I to IV depending upon the presence of 
pleomorphism, mitotic activity, endothelial proliferation and necrosis. Low grade 
astrocytoma often exhibit only one of these factors, whereas grade IV lesions (glioblastoma 
multiforme) usually exhibit all four. Cytogenetic abnormalities are also more prevalent in 
high grade astrocytomas than in low-grade astrocytomas, and this reflects nonrandom 
chromosomal changes that influence the biologic aggressiveness of the tumor. Common 
cytogenetic abnormalities of low grade astrocytoma include losses of chromosome 17p, 
13q (Rb gene) and 22. Anaplastic astrocytoma (AA) is a grade III lesion that exhibits 
increased mitosis with markedly increased cellularity. AA is more common in males than 
females, is usually located in the frontal or temporal lobes and typically presents in the fifth 
decade of life (Moore and Psarros, 2005). 
Malignant astrocytoma represents one of the most devastating tumors affecting 
children and the adults. Malignant astrocytomas usually composed of pleomorphic, 
hyperproliferative infiltrative astrocytes, with areas of necrosis, increased tumor 
angiogenesis and regions of blood brain barrier breakdown. These heterogeneous 
pathological characteristic pose major obstacles to the effective management of gliomas. 
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1.2 Incidence of brain tumor in world 
Based on the World Health Organization (WHO) estimates that the incidence of 
primary malignant brain tumor is 3. 7 per 100 000 per annum for males and 2.6 per 100 000 
per annum for females. This represent an estimated 108 277 males and 81 305 females who 
were diagnosed with a primary malignant brain tumor in 2002, an overall total of 189 582 
individuals. Central Brain Tumor Registry of the United State (CBTRUS) estimates that the 
incidence of malignant brain tumors may climb to 220 568 in 2010 (125 892 males and 94 
676 females). 
The estimated 2010 counts are based on anticipated changes in world population 
demographics and do not accounts for any changes in brain tumor incidence. Non 
malignant brain tumor are often as devastating as malignant brain tumors but were 
routinely collected by cancer surveillance organization in 2002. The CBTRUS has provided 
a preliminary estimate of 157 833 non malignant brain tumor per annum for 2002 
(International Brain Tumor Alliance, 2007). 
Table 1.1: Estimated Number of New Cases of Brain and Central Nervous System Tumor 
Diagnose World-Wide: Primary Malignant (GLOBOCAN 2002) and Non-Malignant 
(CBTRUS- Preliminary Estimate) (Source from International Brain Tumor Alliance, 2007). 
Count 
Overall Male Female 
Malignant 189 582 108 277 81305 
Non-malignant 157 833 58 851 98982 
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1.3 Incidence of brain tumor in Malaysia 
Table 1.2: Brain and Other Nervous System Cancer Incidence per 100 000 populations 
(CR) and Age-standardized incidence (ASR), by sex, Peninsular Malaysia 2003. (Source 
from Chye and Halimah, 2003). 
Sex No. % CR ACR 
Male 249 53.2 2.6 2.8 
Female 219 46.8 2.3 2.5 
Both 468 100 2.4 2.6 
Table 1.3: Brain and Other Nervous System Age specific Cancer Incidence per 100 000 
populations (CR), by sex, Peninsular Malaysia 2003. (Source from Chye and Halimah, 
2003) 
Male Female 
Age, ~ear No. % CR No. % CR 
0-9 33 13.3 1.5 32 14.6 1.5 
10-19 38 15.3 1.9 31 14.2 1.6 
20-29 34 13.7 2.2 26 11.9 1.7 
30-39 43 17.3 3.2 36 16.4 2.7 
40-49 33 13.3 2.9 26 11.9 2.3 
50-59 26 10.4 3.5 36 16.4 5.0 
60-69 29 11.6 7.3 22 10.0 5.3 
70+ 13 5.5 6 10 4.6 3.7 
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Figure 1.1 : Brain and Other Nervous System Age specific Cancer Incidence per 100 000 
populations (CR), by sex, Peninsular Malaysia 2003 (Source from Chye and Halimah, 
2003). 
o Mlle --Female 
Table 1.4: Brain and Other Nervous System Cancer Incidence per 100,000 population (CR) 
and Age-standardized incidence (ASR), by ethnicity and sex, Peninsular Malaysia 2003. 
(Source from Chye and Halimah, 2003). 
Male Female 
Ethic grouE No. % CR ASR No. % CR ASR 
Malay 136 58.9 2.3 2.6 118 57.8 2.0 2.2 
Chinese 79 34.2 3.0 3.0 71 34.8 2.8 2.8 
Indian 16 6.9 1.8 2.3 15 7.4 1.7 1.8 
Table 1.5: Brain and Other Nervous System Age specific Cancer Incidence per 100,000 
population (CR), by ethnicity and sex, Peninsular Malaysia 2003. (Source from Chye and 
Halimah, 2003). 
Age groups, year 
0-9 10-19 20-29 30-39 40-49 50-59 60-69 70+ CumR 
Male Malay 1.6 1.3 2.5 2.5 2.7 3.6 7.4 4.3 0.3 
Chinese 1.3 2.6 1.9 3.5 3.2 3.7 7 7.4 0.3 
Indian 0 0.6 0 2.9 3.4 2.9 9.5 12.1 0.3 
Female Malay 1.2 1.2 1.9 2.8 1.7 5.7 4.6 1.4 0.2 
Chinese 2.5 2.1 1.5 2 2.5 4.4 7.8 4.7 0.3 
Indian 0 1.2 0 2.9 3.3 2.9 0 15.3 0.2 
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A total of 21,464 cancer cases were diagnosed among Malaysians in Peninsular 
Malaysia in the year 2003, comprising 9,400 males and 12,064 females. Cancer occurred at 
all ages. The median age at diagnosis for cancer in Malaysian males was 59 years and 53 
years for Malaysian females. 
There is variation of brain tumor cancer incidence rate between the different ethnic 
groups. The crude incidence rate for brain tumor cancers in Malay male and females were 
58.9 and 57.8 per 100,000 populations respectively; for Chinese male and females 34.2 and 
34.8 per 100,000 population respectively; and for the Indian male and females 6.9 and 7.4 
per 100,000 population respectively (Chye and Halimah, 2003). 
1.4 Incidence of brain tumor in HUSM 
The classification of brain tumor was based on the recent World Health 
Organization classification. The brain tumor that reported in the Hospital of University 
Science Malaysia (HUSM) was low (0.4 per I 00 000) population), with no significant 
gender preponderance. Neuroglial tumor (35%) was the most common brain tumors 
followed by meningiomas (33%), medulloblastomas (12%) and schwannomas (6%). The 
incidence of brain tumor with a size less than 4 em in diameter and less than 30 cc in 
volume was 68.2% and 58.7% respectively. Primary brain tumors were more common in 
male and female except meningiomas and nerve sheath tumors, which were more common 
in the female. The incidence rate by age was low in the teens; this rose steadily to a peak in 
the fourth decade and then declined somewhat after the age of 60. Headache, vomiting, 
papilloedema and cranial nerve deficits were the common presenting features (Mohd R. 
Yusoff et al., 1998) 
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Figure 1.2: Incidence of brain tumor in HUSM 
Incidence of Brain Tumor in HUSM 
• neuroglial tumor • meningiomas medulloblastoma • schwannomas • others 
1.5 Incidence of Glioma by anatomic location 
The anatomic location of a glioma influences prognosis and treatment options. The 
gliomas were located in the frontal lobe in 40% of the cases, temporal in 29%, parietal in 
14% and occipital lobe in 3% with 14% in the deeper structure. The difference in 
distribution between lobes remained after adjustment for their tissue volume: the tumor: 
volume ratio was 4.5 for the frontal, 4.8 for temporal and 2.3 for parietal relative to the 
occipital lobe. The area with the densest occurrence was the anterior subcortical brain. 
The crude incidence rate of gliomas (per 1 00,000) was 1.68 (95% CI, 1.36-2.00) for 
the frontal lobe, 1.21 (95% CI, 0.94-1.48) for the temporal lobe, 0.58 (95% CI, 0.39-D. 77) 
for the parietal lobe, and 0.13 (95% CI, 0.04-0.21) for the occipital lobe. Glioma were 
located more frequently in the right hemisphere (51%) than in the left ( 40%) while 9% of 
glioma were in the center of the brain (Larjavaara et al., 2007). 
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